Alzheimer’s Disease Clinical Trials

Clinical Trials for Alzheimer's Disease

The 108 clinical trials listed here include 65 that have not yet started recruiting patients or are just now seeking volunteers to participate and another 43 that are active, but not recruiting new patients. This information is potentially valuable to patients still seeking possible treatments for Alzheimer’s disease. It provides a new therapeutic option to discuss with physicians. Those interested in obtaining more information about certain trials can use the URL code listed for each trial to log onto www.clinicaltrials.gov, the clinical trials database of the National Institutes of Health.

Study 1 – Recruiting
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
http://ClinicalTrials.gov/show/NCT01561430

Study 2 – Not yet recruiting
A Phase II Trial of Florbetapir (18F) Positron Emission Tomography (PET) Imaging in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)
http://ClinicalTrials.gov/show/NCT01662882

Study 3 – Active, not recruiting
Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects with Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease
http://ClinicalTrials.gov/show/NCT01028053

Study 4 – Active, not recruiting
Trial of Novel Oral Zinc Cysteine Preparation in Alzheimer's Disease
http://ClinicalTrials.gov/show/NCT01099332

Study 5 – Active, not recruiting
Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease
http://ClinicalTrials.gov/show/NCT01227564

Study 6 – Active, not recruiting
Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Mild to Moderate Alzheimer's Disease
http://ClinicalTrials.gov/show/NCT01284387

Study 7 – Enrolling by invitation
A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's Disease
http://ClinicalTrials.gov/show/NCT00937352

Study 8 – Active not recruiting
Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
http://ClinicalTrials.gov/show/NCT00829374

Study 9 – Recruiting
Study of Huperzine A Sustained-Release Tablets in Patients With Alzheimer's Disease
http://ClinicalTrials.gov/show/NCT01282619

Study 10 – Recruiting
VI-1121 for the Treatment Alzheimer's Disease
http://ClinicalTrials.gov/show/NCT01428362

Study 11 – Active, not recruiting
Study Evaluating Safety, Tolerability, And Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
http://ClinicalTrials.gov/show/NCT00479557

Study 12 – Active, not recruiting
Amyloid Imaging And Safety Study Of Subcutaneous Bapineuzumab In Subjects With Mild to Moderate Alzheimer's Disease
http://ClinicalTrials.gov/show/NCT01254773

Study 13 – Recruiting
Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease
http://ClinicalTrials.gov/show/NCT01193608

Study 14 – Active, not recruiting
Safety, Tolerability, And Immunogenicity Study Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease
http://ClinicalTrials.gov/show/NCT00959192

Study 15 – Recruiting
Long Term Extension Study Evaluating Safety, Tolerability And Immunogenicity Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease
http://ClinicalTrials.gov/show/NCT01238991

Study 16 – Not yet recruiting
Safety, Tolerability, Pharmacokinetics of EVP-0962 and Effects of EVP-0962 on Cerebral Spinal Fluid Amyloid Concentrations in Healthy Subjects and in subjects With Mild Cognitive Impairment or Early Alzheimer's Disease
http://ClinicalTrials.gov/show/NCT01661673

Study 17 – Recruiting
Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease
http://ClinicalTrials.gov/show/NCT01369225

Study 18 – Recruiting
Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease
http://ClinicalTrials.gov/show/NCT01569516

Study 19 – Recruiting
Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease
http://ClinicalTrials.gov/show/NCT00876863

Study 20 – Recruiting
A Phase 2a Study to Evaluate the Effect of Rilapladib (SB-659032) in Alzheimer's Disease
http://ClinicalTrials.gov/show/NCT01428453

Study 21 – Active, not recruiting
European Study of 3APS in Mild to Moderate Alzheimer's Disease Patients
http://ClinicalTrials.gov/show/NCT00217763

Study 22 – Recruiting
3-month Study of MSDC-0160 Effects on Brain Glucose Utilization, Cognition & Safety in Subjects With Alzheimer's Disease
http://ClinicalTrials.gov/show/NCT01374438

Study 23 – Active, not recruiting
Double-Blind, Placebo-Controlled Study of Oral Dimebon in Subjects With Mild to Moderate Alzheimer's Disease
http://ClinicalTrials.gov/show/NCT00377715

Study 24 – Not yet recruiting
Safety Study of TRx0237 in Patients Already Taking Medications for Mild and Moderate Alzheimer's Disease
http://ClinicalTrials.gov/show/NCT01626391]

Study 25 – Active, not recruiting
Safety and Efficacy Study of Ladostigil in Mild to Moderate Probable Alzheimer's Disease
http://ClinicalTrials.gov/show/NCT01354691

Study 26 – Active, not recruiting
A Safety and Efficacy Study of Oral Dimebon in Patients With Mild-To-Moderate Alzheimer's Disease
http://ClinicalTrials.gov/show/NCT00675623

Study 27 – Active, not recruiting
Effect of PF-04360365 On ABETA In Patients With Alzheimer's Disease And Healthy Volunteers
http://ClinicalTrials.gov/show/NCT01005862

Study 28 – Active, not recruiting
Effect of EGb761® on Brain Glucose Metabolism in Three Groups of Elderly With: Memory Complaint, Mild Alzheimer's Disease, and Cognitively Normal
http://ClinicalTrials.gov/show/NCT00814346

Study 29 – Active, not recruiting
A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease
http://ClinicalTrials.gov/show/NCT00818662

Study 30 – Active, not recruiting
Efficacy of Circadin® 2 mg in Patients With Mild to Moderate Alzheimer Disease Treated With AChE Inhibitor
http://ClinicalTrials.gov/show/NCT00940589

Study 31 –Recruiting
A Randomized SAD and MAD Study Evaluating the Safety and Tolerability of RPh201 in Healthy Subjects and in Adults With Alzheimer's Disease
http://ClinicalTrials.gov/show/NCT01513967

Study 32 – Recruiting
A Study to Evaluate Albumin and Immunoglobulin in Alzheimer's Disease
http://ClinicalTrials.gov/show/NCT01561053

Study 33 – Active, not recruiting
Study Evaluating ACC-001 in Japanese Patients With Mild To Moderate Alzheimer's Disease
http://ClinicalTrials.gov/show/NCT00752232

Study 34 – Active, not recruiting
Computer-Based Training for Mild Alzheimer’s Disease
http://ClinicalTrials.gov/show/NCT00319891

Study 35 – Recruiting
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
http://ClinicalTrials.gov/show/NCT00960531

Study 36 – Recruiting
Long Term Extension Study Evaluating Safety, Tolerability and Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
http://ClinicalTrials.gov/show/NCT00955409

Study 37 – Recruiting
Deep Transcranial Magnetic Stimulation for Treatment of Alzheimer's Disease
http://ClinicalTrials.gov/show/NCT01179373

Study 38 – Active, not recruiting
Continued Safety Monitoring of Solanezumab in Alzheimer's Disease
http://ClinicalTrials.gov/show/NCT01127633

Study 39 – Active, not recruiting
Safety and Efficacy of ORM-12741 in Patients With Alzheimer's Disease
http://ClinicalTrials.gov/show/NCT01324518

Study 40 – Recruiting
Advance DBS-f in Patients With Mild Probable Alzheimer's Disease
http://ClinicalTrials.gov/show/NCT01608061

Study 41 – Active, not recruiting
Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
http://ClinicalTrials.gov/show/NCT00498602

Study 42 – Active, not recruiting
Study of Combination Therapy With Dimebon and Donepezil (Aricept) in Patients With Alzheimer's Disease
http://ClinicalTrials.gov/show/NCT00253227

Study 43 – Active, not recruiting
Evaluation of 3APS in Patients With Mild to Moderate Alzheimer’s Disease
http://ClinicalTrials.gov/show/NCT00088673

Study 44 – Recruiting
Single Ascending Dose Study of BIIB037 in Subjects With Alzheimer's Disease
http://ClinicalTrials.gov/show/NCT01397539

Study 45 – Recruiting
Phase 3 IGIV, 10% in Alzheimer´s Disease
http://ClinicalTrials.gov/show/NCT01524887

Study 46 – Enrolling by invitation
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease
http://ClinicalTrials.gov/show/NCT01527916

Study 47 – Recruiting
Evaluation of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease
http://ClinicalTrials.gov/show/NCT01600859

Study 48 – Active, not recruiting
Open-Label Extension of the Phase III Study With Tramiprosate (3APS) in Patients With Mild to Moderate Alzheimer's Disease
http://ClinicalTrials.gov/show/NCT00314912

Study 49 – Active, not recruiting
A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's Disease
http://ClinicalTrials.gov/show/NCT00890890

Study 50 – Active, not recruiting
A Double-blind, Placebo-controlled, 2-year Study of Galantamine Used to Treat Patients With Mild to Moderate Alzheimer's Disease.
http://ClinicalTrials.gov/show/NCT00679627

Study 51 – Recruiting
Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
http://ClinicalTrials.gov/show/NCT01492374

Study 52 – recruiting
A Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's Disease
http://ClinicalTrials.gov/show/NCT01397578

Study 53 – Active, not recruiting
Clinical- and Immunological Activity, Safety and Tolerability of Different Doses / Formulations of AFFITOPE AD02 in Early Alzheimer's Disease
http://ClinicalTrials.gov/show/NCT01117818

Study 54 – Recruiting
A Safety Study of TTP4000 in Subjects With Alzheimer's Disease
http://ClinicalTrials.gov/show/NCT01548430

Study 55 – Active, not recruiting
Encapsulated Cell Biodelivery of Nerve Growth Factor to Alzheimer´s Disease Patients
http://ClinicalTrials.gov/show/NCT01163825

Study 56 – Recruiting
Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)
http://ClinicalTrials.gov/show/NCT01466088

Study 57 – Recruiting
A 24-Week Efficacy, Safety and Tolerability of Rivastigmine Patch Study in Patients With Probable Alzheimer's Disease
http://ClinicalTrials.gov/show/NCT01399125

Study 58 – Active, not recruiting
AAB-001 (Bapineuzumab) Open-Label, Long-Term Extension Study in Patients With Mild to Moderate Alzheimer's Disease
http://ClinicalTrials.gov/show/NCT00606476

Study 59 – Recruiting
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
http://ClinicalTrials.gov/show/NCT01549834

Study 60 – Recruiting
A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)
http://ClinicalTrials.gov/show/NCT01343966

Study 61 – Not yet recruiting
AC-1204 Long-term Efficacy Response Trial (ALERT Protocol)
http://ClinicalTrials.gov/show/NCT01211782

Study 62 – Recruiting
Safety Study of HPP854 in Subjects With Mild Cognitive Impairment or a Diagnosis of Mild Alzheimer's Disease
http://ClinicalTrials.gov/show/NCT01482013

Study 63 – Not yet recruiting
Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)
http://ClinicalTrials.gov/show/NCT01614886

Study 64 – Recruiting
A Study of Gantenerumab in Patients With Prodromal Alzheimer's Disease
http://ClinicalTrials.gov/show/NCT01224106

Study 65 – Recruiting
A 24-weeks, Multi-center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride in Chinese Subjects With Severe Alzheimer's Disease
http://ClinicalTrials.gov/show/NCT01404169

Study 66 – Recruiting
Compare the Efficacy and Safety of Donepezil Hydrochloride 23 mg Treatment With Continuation of Donepezil Hydrochloride 10 mg Treatment in Japanese Subjects With Severe Alzheimer's Disease
http://ClinicalTrials.gov/show/NCT01539031

Study 67 – Recruiting
Study to Evaluate Dietary Supplementation With a Version of Anatabloc(R) in Subjects With Alzheimer's Disease
http://ClinicalTrials.gov/show/NCT01669876

Study 68 – Recruiting
Safety, Efficacy and Dose Titration of Sodium Oligo-mannurarate Capsule on Mild to Moderate Alzheimer's Disease
http://ClinicalTrials.gov/show/NCT01453569

Study 69 – Active, not recruiting
Efficacy, Safety and Tolerability of Tideglusib to Treat Mild-to-Moderate Alzheimer's Disease Patients
http://ClinicalTrials.gov/show/NCT01350362

Study 70 – Recruiting
Single and Repeated Dosing Study to Assess the Safety and the Concentration-time Profile of SAR228810 in Alzheimer's Patients
http://ClinicalTrials.gov/show/NCT01485302

Study 71 – Active, not recruiting
Safety and Tolerability of Dimebon in Patients on Memantine, and Memantine Plus Donepezil
http://ClinicalTrials.gov/show/NCT00829816

Study 72 – Active, not recruiting
Safety, Tolerability and Abeta-specific Antibody Response of Repeated i.m. Injections of Adjuvanted CAD106 in Mild Alzheimer Patients
http://ClinicalTrials.gov/show/NCT01097096

Study 73 – Active, not recruiting
Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients
http://ClinicalTrials.gov/show/NCT00676143

Study 74 – Recruiting
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
http://ClinicalTrials.gov/show/NCT00667810

Study 75 – Recruiting
A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients
http://ClinicalTrials.gov/show/NCT00998764

Study 76 – Recruiting
A Long-Term Safety And Tolerability Study Of Bapineuzumab In Alzheimer Disease Patients
http://ClinicalTrials.gov/show/NCT00996918

Study 77 – Recruiting
A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment
http://ClinicalTrials.gov/show/NCT01548287

Study 78 – Recruiting
A Non-drug Methods Study in Patients With Alzheimer's Disease
http://ClinicalTrials.gov/show/NCT01459016

Study 79 – Recruiting
A Confirmatory Trial of SK-PC-B70M in Mild to Moderate Alzheimer's Disease
http://ClinicalTrials.gov/show/NCT01249196

Study 80 – Active, not recruiting
A Study Versus E2020 10mg Followed by an Open-label Extension Phase to Explore the Safety of E2020 SR 23 mg in Japanese Subjects With Severe Alzheimer's Type Dementia
http://ClinicalTrials.gov/show/NCT01276353

Study 81 – Recruiting
A Multiple-dose Study of RO4909832 in Japanese Alzheimer's Disease Patients
http://ClinicalTrials.gov/show/NCT01656525

Study 82 – Active, not recruiting
Effect of Different Doses of SAR110894D on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
http://ClinicalTrials.gov/show/NCT01266525

Study 83 – Not yet recruiting
Tolerability of Rivastigmine Before and After Switching From Oral Formulation to Transdermal Patch in Alzheimer's Dementia
http://ClinicalTrials.gov/show/NCT01585272

Study 84 – Not yet recruiting
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
http://ClinicalTrials.gov/show/NCT01584440

Study 85 – Active, not recruiting
A Biomarker Study of Solanezumab in Patients With and Without Alzheimer's
http://ClinicalTrials.gov/show/NCT01148498

Study 86 – Active, not recruiting
Study Evaluating The Long-Term Safety And Efficacy Of Subcutaneous Bapineuzumab
http://ClinicalTrials.gov/show/NCT00916617

Study 87 – Active, not recruiting
A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease
http://ClinicalTrials.gov/show/NCT00235716

Study 88 – Active, not recruiting
iCare Stress Management e-Training for Dementia Family Caregivers
http://ClinicalTrials.gov/show/NCT01378195

Study 89 – Recruiting
Safety and Tolerability of Etanercept in Alzheimer's Disease
http://ClinicalTrials.gov/show/NCT01068353

Study 90 – Recruiting
Deep Transcranial Magnetic Stimulation in Patients With Alzheimer's Disease
http://ClinicalTrials.gov/show/NCT00753662

Study 91 – Active, not recruiting
Prevention of Cognitive Decline in Alzheimer's Disease by Ingested Interferon Alpha
http://ClinicalTrials.gov/show/NCT00031018

Study 92 – Recruiting
A Study of Florbetapir (18F) in Japanese Healthy Volunteers
http://ClinicalTrials.gov/show/NCT01660815

Study 93 – Active, not recruiting
Phase III Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid Compared to Histopathology
http://ClinicalTrials.gov/show/NCT01020838

Study 94 – Recruiting
A Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study
http://ClinicalTrials.gov/show/NCT01230853

Study 95 – Recruiting
Study of the Pharmacokinetics and Pharmacodynamics of POSIPHEN® in Subjects With Amnestic Mild Cognitive Impairment
http://ClinicalTrials.gov/show/NCT01072812

Study 96 – Enrolling by invitation
Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Open Label Extension (CT04 OLEP)
http://ClinicalTrials.gov/show/NCT01421056

Study 97 – Enrolling by invitation
Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Prolonged Open Label Extension Phase
http://ClinicalTrials.gov/show/NCT01602393

Study 98 – Active, not recruiting
A Two-Part, Single-Dose Study of the Pharmacokinetics of MK-8931 in Subjects With Renal Insufficiency (MK-8931-009 [P08535])
http://ClinicalTrials.gov/show/NCT01537757

Study 99 – Recruiting
A Randomized, Double-blind, Placebo-controlled, Sequential Ascending, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2212 in Healthy Subjects
http://ClinicalTrials.gov/show/NCT01221259

Study 100 – Recruiting
TMS Stimulation and Cognitive Training in Alzheimer Patients
http://ClinicalTrials.gov/show/NCT01168245

Study 101 – Recruiting
An Open Positron Emission Tomography Study to Assess the Effects of Varying Mass of AZD4694 on Radioligand Binding Parameters in Healthy Volunteers and Patients With Alzheimer's Disease
http://ClinicalTrials.gov/show/NCT01325402

Study 102 – Recruiting
Alzheimer and Sleep
http://ClinicalTrials.gov/show/NCT00750529

Study 103 – Recruiting
Effects of a Combined Transcranial Magnetic Stimulation (TMS) and Cognitive Training in Alzheimer Patients
http://ClinicalTrials.gov/show/NCT01504958

Study 104 – Recruiting
Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment
http://ClinicalTrials.gov/show/NCT00149175

Study 105 – Recruiting
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
http://ClinicalTrials.gov/show/NCT01518374

Study 106 – Recruiting
A 3 Year Study to Evaluate the Safety and Efficacy of Low Dose Ladostigil in Patients With Mild Cognitive Impairment (MCI)
http://ClinicalTrials.gov/show/NCT01429623

Study 107 – Active, not recruiting
Rosiglitazone Effects on Cognition for Adults in Later Life
http://ClinicalTrials.gov/show/NCT00242593

Study 108 – Recruiting
The Effect of Melatonin on Cognitive Function in Patients Diagnosed With Mild Cognitive Impairment
http://ClinicalTrials.gov/show/NCT00544791

 

* Source: www.clinicaltrials.gov; Search criteria: Alzheimer’s disease, Phase I, II, III; industry only.  Included are only active clinical trials -- active, not recruiting; recruiting, not yet recruiting, and enrolling by invitation. Search performed 8/22/2012.

 

More On PhRMA — powered by PhRMApedia